-
公开(公告)号:US20210054457A1
公开(公告)日:2021-02-25
申请号:US16826030
申请日:2020-03-20
Applicant: LineaGen, Inc. , University of Utah Research Foundation
Inventor: Mark Leppert , William McMahon , Nori Matsunami , Michael S. Paul , Alex S. Lindell
IPC: C12Q1/6883
Abstract: The present disclosure relates to the identification of a subject that is affected with, or predisposed to, autism or to one or more autism spectrum disorders (ASD). The present disclosure includes methods related to the association of certain genetic markers with autism and/or ASD. More particularly, the present disclosure is related to methods and diagnostic tests for diagnosing or predicting ASD in an individual.
-
公开(公告)号:US20220033903A1
公开(公告)日:2022-02-03
申请号:US17198171
申请日:2021-03-10
Applicant: Lineagen, Inc.
Inventor: Karen S. Ho , Charles H. Hensel
IPC: C12Q1/6883
Abstract: The present invention relates generally to genetic markers for duplication and/or deletion syndromes, such as Wolf-Hirschhorn syndrome (WHS), in particular to copy number variant genetic markers for selecting a patient for therapy for the particular therapy, or predicting the response of a subject to a particular therapy.
-
公开(公告)号:US20210395823A1
公开(公告)日:2021-12-23
申请号:US17307793
申请日:2021-05-04
Applicant: Lineagen, Inc.
Inventor: Charles H. Hensel
IPC: C12Q1/6883
Abstract: The present invention relates generally to genetic markers for autism spectrum disorders and other childhood developmental delay disorders, in particular to copy number variant genetic markers for autism spectrum disorders.
-
4.
公开(公告)号:US20210212960A1
公开(公告)日:2021-07-15
申请号:US17028306
申请日:2020-09-22
Applicant: Lineagen, Inc.
Inventor: Karen S. Ho , E. Robert Wassman
IPC: A61K31/05 , A61P25/02 , A61K31/4415 , A61P25/08 , A61K31/19 , A61K31/675 , C12Q1/6883
Abstract: The present invention provides methods related to Wolf-Hirschhorn syndrome (WHS), in particular to a 197 kbp chromosomal deletion useful for selecting a patient for anti-seizure therapy (e.g., cannabidiol, vitamin B6, and butyrate), for selecting a particular anti-seizure therapy, and for predicting the response of a subject to a particular anti-seizure therapy.
-
公开(公告)号:US20210222245A1
公开(公告)日:2021-07-22
申请号:US17099195
申请日:2020-11-16
Applicant: LineaGen, Inc. , University of Utah Research Foundation
Inventor: Mark Leppert , William McMahon , Nori Matsunami , Michael S. Paul , Alex S. Lindell
IPC: C12Q1/6883
Abstract: The present disclosure relates to the identification of a subject that is affected with, or predisposed to, autism or to one or more autism spectrum disorders (ASD). The present disclosure includes methods related to the association of certain genetic markers with autism and/or ASD. More particularly, the present disclosure is related to methods and diagnostic tests for diagnosing or predicting ASD in an individual.
-
公开(公告)号:US20200095639A1
公开(公告)日:2020-03-26
申请号:US16408154
申请日:2019-05-09
Applicant: LINEAGEN, INC.
Inventor: Charles H. HENSEL
IPC: C12Q1/6883
Abstract: The present invention relates generally to genetic markers for autism spectrum disorders and other childhood developmental delay disorders, in particular to copy number variant genetic markers for autism spectrum disorders.
-
公开(公告)号:US20170175189A1
公开(公告)日:2017-06-22
申请号:US15104897
申请日:2014-12-22
Applicant: LINEAGEN, INC.
Inventor: Charles H. HENSEL
IPC: C12Q1/68 , G06F19/18 , G06F19/20 , G01N33/483
CPC classification number: C12Q1/6883 , C12Q2600/156 , G01N33/483 , G16B20/00 , G16B25/00
Abstract: Methods and compositions for the detection of single nucleotide polymorphisms (SNP) to determine whether the subject has autism spectrum disorder (ASD), is likely to develop ASD, or to classify a subject as having a particular ASD subtype. The presence and/or absence of the one or more SNPs is compared to the presence and/or absence of the SNPs in at least one sample training set(s), where the comparing step comprises applying a statistical algorithm which comprises determining a correlation between the SNP data obtained from the sample and the SNP data from the at least one training set.
-
公开(公告)号:US20210230693A1
公开(公告)日:2021-07-29
申请号:US16951470
申请日:2020-11-18
Applicant: LINEAGEN, INC.
Inventor: Charles H. Hensel
IPC: C12Q1/6883 , G16B20/00 , G16B25/00 , G01N33/483
Abstract: Methods and compositions for the detection of single nucleotide polymorphisms in a sample are provided. The methods and compositions are employed to determine whether the subject has autism spectrum disorder (ASD), is likely to develop ASD, or to classify a subject as having a particular ASD subtype. In one method of the invention, a sample is probed for one or more SNPs in Table 1, Table 2, Table 3, Table 6 or Table 7 at the nucleic acid level by performing a polymerase chain reaction (PCR) with primers specific to the SNPs. The presence and/or absence of the one or more SNPs is then compared to the presence and/or absence of the of the SNPs in at least one sample training set(s), where the comparing step comprises applying a statistical algorithm which comprises determining a correlation between the SNP data obtained from the sample and the SNP data from the at least one training set. The sample is diagnosed as ASD positive or ASD negative based on the results of the statistical algorithm.
-
9.
公开(公告)号:US20190247326A1
公开(公告)日:2019-08-15
申请号:US16335234
申请日:2017-09-19
Applicant: Lineagen, Inc.
Inventor: Karen S. HO , E. Robert WASSMAN
IPC: A61K31/05 , A61K31/675 , A61K31/19 , C12Q1/6883 , A61P25/08
CPC classification number: A61K31/05 , A61K31/19 , A61K31/4415 , A61K31/675 , A61P25/02 , A61P25/08 , C12Q1/6883 , C12Q2600/106 , C12Q2600/118
Abstract: The present invention provides methods related to Wolf-Hirschhom syndrome (WHS), in particular to a 197 kbp chromosomal deletion useful for selecting a patient for anti-seizure therapy (e.g., cannabidiol, vitamin B6, and butyrate), for selecting a particular anti-seizure therapy, and for predicting the response of a subject to a particular anti-seizure therapy.
-
公开(公告)号:US20180073075A1
公开(公告)日:2018-03-15
申请号:US15713462
申请日:2017-09-22
Applicant: LineaGen, Inc.
Inventor: Bradley Todd Webb , Barbara K. Zedler , Edward Lenn Murrelle , Mark Leppert , Edwin J. C. G. van den Oord , Daniel E. Adkins , Willie J. McKinney
IPC: C12Q1/68 , G01N33/574
CPC classification number: C12Q1/6876 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172 , G01N33/57423 , G01N2800/104 , G01N2800/12 , G01N2800/122 , G01N2800/323 , G01N2800/382
Abstract: The technology provided herein relates to the SNPs identified as described herein, both singly and in combination, as well as to the use of these SNPs, and others in linkage disequilibrium with these SNPs, for diagnosis, prediction of clinical course, and/or treatment response for pulmonary disease such as COPD, development of new treatments for pulmonary disease such as COPD based upon comparison of the variant and normal versions of the gene or gene product, and development of cell-culture based and animal models for research and treatment of pulmonary disease such as COPD. The technology provided herein further relates to novel compounds, pharmaceutical compositions, and kits for use in the diagnosis, treatment, and evaluation of such disorders.
-
-
-
-
-
-
-
-
-